Phosphodiesterase isozymes molecular targets for novel antiasthma agents

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 2, 1998, Pages 351-370

  Torphy, Theodore J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; 1 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 1 PHENYL 2 (4 PYRIDYL)ETHANE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANTIASTHMATIC AGENT; ATIZORAM; BENAFENTRINE; BRL 61063; BRL 616063; BRONCHODILATING AGENT; CILOMILAST; CILOSTAMIDE; CILOSTAZOL; DENBUFYLLINE; DIPYRIDAMOLE; ENOXIMONE; MILRINONE; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; NITRAQUAZONE; PHENOTHIAZINE; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; ROLIPRAM; SIGUAZODAN; SKF 96231; THEOPHYLLINE; TIBENELAST; TREQUINSIN; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST; ZARDAVERINE;

ADULT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME KINETICS; ENZYME REGULATION; ENZYME STRUCTURE; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; INFLAMMATORY CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 0031914520     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.2.9708012     Document Type: Review

References (290)

1. Sutherland, E. W., and T. W. Rall. 1958. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232:1077-1091.
2. Beavo, J. A., G. Hardman, and E. W. Sutherland. 1970. Hydrolysis of cyclic guanosine and adenosine 3′,5′-monophosphates by rat and bovine tissues. J. Biol. Chem. 245:5649-5655.
3. Thompson, W. J., and M. M. Appleman. 1971. Characterization of cyclic nucleotide phosphodiesterases of rat tissues. J. Biol. Chem. 246: 3145-3150.
4. Appleman, M. M., W. J. Thompson, and T. R. Russell. 1973. Cyclic nucleotide phosphodiesterases. In P. Greengard and G. A. Robison, editors. Advances in Cyclic Nucleotide Research. Raven Press, New York. 65-96.
5. Levin, R. M., and B. Weiss. 1976. Mechanism by which psychotropic drugs inhibit adenosine cyclic 3′,5′-monophosphate phosphodiesterase of brain. Mol. Pharmacol. 12:581-589.
6. Hidaka, H., T. Tanaka, and H. Itoh. 1984. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases. Trends Pharmacol. Sci. 5:237-239.
7. Wells, J. N., J. E. Garst, and G. L. Kramer. 1981. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthines. J. Med. Chem. 24:954-958.
8. Wood, M. A., and M. L. Hess. 1989. Review: Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. Am. J. Med. Sci. 297:105-113.
9. Charbonneau, H., N. Beier, K. A. Walsh, and J. A. Beavo. 1986. Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species. Proc. Natl. Acad. Sci. U.S.A. 83:9308-9312.
10. Beavo, J. A. 1995. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:725-748.
11. Conti, M., G. Nemoz, C. Sette, and E. Vicini. 1995. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16:370-389.
12. Polson, J. B., J. J. Krzanowski, A. L. Goldman, and A. Szentivanyi. 1978. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin. Exp. Pharmacol. Physiol. 5: 535-539.
13. Persson, C. G. A. 1986. Overview of effects of theophylline. J. Allergy Clin. Immunol. 78:780-787.
14. Church, M. K., R. L. Featherstone, M. J. Cushley, J. S. Mann, and S. T. Holgate. 1986. Relationships between adenosine, cyclic nucleotides and xanthines in asthma. J. Allergy Clin. Immunol. 78:670-675.
15. Howell, R. E., W. T. Muehsam, and W. J. Kinnier. 1990. Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci. 46:563-568.
16. Torphy, T. J., and B. J. Undem. 1991. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-523.
17. Manganiello, V. C., T. Murata, M. Taira, P. Belfrage, and E. Degerman. 1995. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch. Biochem. Biophys. 322:1-13.
18. Beavo, J. A., M. Conti, and R. J. Heaslip. 1994. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:399-405.
19. Thompson, W. J. 1991. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol. Ther. 51:13-33.
20. Bolger, G. B. 1994. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell. Signal. 6:851-859.
21. Kovala, T., B. D. Sanwal, and E. H. Ball. 1997. Recombinant expression of a type-IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants. Biochemistry 36:2968-2976.
22. Degerman, E., and P. Belfrage. 1987. Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J. Biol. Chem. 262:5797-5807.
23. Manganiello, V. C., C. J. Smith, E. Degerman, V. Vasta, H. Tornqvist, and P. Belfrage. 1991. Molecular mechanisms involved in the antilipolytic action of insulin: phosphorylation and activation of a particulate adipocyte cAMP phosphodiesterase. Adv. Exp. Med. Biol. 293: 239-248.
24. Erneux, C., J. Van Sande, F. Miot, P. Cochaux, C. Decoster, and J. E. Dumont. 1985. A mechanism in the control of intracellular cAMP level: the activation of a calmodulin-sensitive phosphodiesterase by a rise of intracellular free calcium. Mol. Cell. Endocrinol. 43:123-134.
25. Tanner, L. I., K. Harden, J. N. Wells, and M. W. Martin. 1986. Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells. Mol. Pharmacol. 29: 455-460.
26. MacFarland, R. T., B. D. Zelus, and J. A. Beavo. 1991. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J. Biol. Chem. 266:136-142.
27. Whalin, M. E., J. G. Scammell, S. J. Strada, and W. J. Thompson. 1991. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells. Mol. Pharmacol. 39:711-717.
28. Harrison, S. A., D. H. Reifsnyder, B. Gallis, G. G. Gadd, and J. A. Beavo. 1986. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol. Pharmacol. 29:506-514.
29. Maurice, D. H., and R. J. Haslam. 1990. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. 37:671-681.
30. Maurice, D. H., D. Crankshaw, and R. J. Haslam. 1991. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur. J. Pharmacol. 192:235-242.
31. Fernandes, L. R., J. L. Ellis, and B. J. Undem. 1994. Potentiation of nonadrenergic noncholinergic relaxation of human isolated bronchus by selective inhibitors of phosphodiesterase isozymes. Am. J. Respir. Crit. Care Med. 150:1384-1390.
32. Sharma, R. K., and J. H. Wang. 1985. Differential regulation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase. Proc. Natl. Acad. Sci. U.S.A. 82:2603-2607.
33. 2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 264:10884-10887.
34. Sette, C., E. Vicini, and M. Conti. 1994. The rat PDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem. 269:18271-18274.
35. Thomas, M. K., S. H. Francis, and J. D. Corbin. 1990. Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J. Biol. Chem. 265:14971-14978.
36. Thomas, M. K., S. H. Francis, and J. D. Corbin. 1990. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J. Biol. Chem. 265:14964-14970.
37. Burns, F., I. W. Rodger, and N. J. Pyne. 1992. The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung. Biochem. J. 283:487-491.
38. Schneider, H. H., R. Schmiechen, M. Brezinski, and J. Seidler. 1986. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 127:105-115.
39. Michaeli, T., T. J. Bloom, T. Martins, K. Loughney, K. Ferguson, M. Riggs, L. Rodgers, J. A. Beavo, and M. Wigler. 1993. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J. Biol. Chem. 268:12925-12932.
40. Ichimura, M., and H. Kase. 1993. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem. Biophys. Res. Commun. 193:985-990.
41. Giembycz, M. A. 1992. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem. Pharmacol. 43:2041-2051.
42. Nicholson, C. D., and M. Shahid. 1994. Inhibitors of cyclic nueleotide phosphodiesterase isoenzymes: their potential utility in the therapy of asthma. Pulm. Pharmacol. 7:1-17.
43. Milatovich, A., G. Bolger, T. Michaeli, and U. Francke. 1994. Chromosome localization of genes for five cAMP-specific phosphodiesterases in man and mouse. Somat. Cell Mol. Genet. 20:75-86.
44. m, rolipram-sensitive, cyclic AMP-specific phosphodiesterase from human brain: cloning and expression of cDNA, preliminary biochemical characterization and tissue distribution of mRNA. J. Biol. Chem. 268:6470-6476.
45. Bolger, G., T. Michaeli, T. Martins, T. St. John, B. Steiner, L. Rodgers, M. Riggs, M. Wigler, and K. Ferguson. 1993. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol. Cell Biol. 13:6558-6571.
46. Muller, T., P. Engels, and J. R. Fozard. 1996. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol. Sci. 17:294-298.
47. Obernolte, R., S. Bhakta, R. Alvarez, C. Bach, P. Zuppan, M. Mulkins, K. Jarnagin, and E. R. Shelton. 1993. The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDEIV) reveals a multigene family. Gene 129:239-247.
48. Jacobitz, S., M. M. McLaughlin, G. P. Livi, M. Burman, and T. J. Torphy. 1996. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. 50:891-899.
49. Engels, P., M. Sullivan, T. Muller, and H. Lubbert. 1995. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett. 358:305-310.
50. Engels, P., K. Fichtel, and H. Lubbert. 1994. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350:291-295.
51. m rolipram-sensitive cAMP phosphodiesterase. Mol. Cell Biol. 10:2678-2686.
52. B2) in brains: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem. J. 304: 3399-3406.
53. Manning, C. D., M. M. McLaughlin, G. P. Livi, L. B. Cieslinski, T. J. Torphy, and M. S. Barnette. 1996. Prolonged beta-adrenoceptor stimulation upregulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J Pharmacol. Exp. Ther. 276:810-818.
54. 2: implications for the therapeutic use of beta-adrenoceptor agonists. J. Biol. Chem. 270:23598-23604.
55. Verghese, M. W., R. T. McConnell, J. M. Lenhard, L. Hamacher, and S. L. Jin. 1995. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol. Pharmacol. 47:1164-1171.
56. Horton, Y. M., M. Sullivan, and M. D. Houslay. 1995. Molecular-cloning of a novel splice variant of human type-IVA (PDE-IVA) cyclic-AMP phosphodiesterase and localization of the gene to the P13.1-Q12 region of human-chromosome-19. Biochem. J. 308:683-691.
57. Bushnik, T., and M. Conti. 1996. Role of multiple cAMP-specific phosphodiesterase variants. Biochem. Soc. Trans. 24:1014-1019.
58. Houslay, M. D. 1996. N-Terminal alternatively spliced regions of PDE4A cAMP-specific phosphodiesterases determine intracellular targeting and regulation of catalytic activity. Biochem. Soc. Trans. 24:980-986.
59. Alvarez, R., C. Sette, D. Yang, R. M. Eglen, R. Wilhelm, E. R. Shelton, and M. Conti. 1995. Activation and selective inhibition of a cyclic AMP phosphodiesterase, PDE-4D3. Mol. Pharmacol. 48:616-622.
60. Sette, C., and M. Conti. 1996. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase: involvement of serine 54 in the enzyme activation. J. Biol. Chem. 271:16526-16534.
61. Shakur, Y., M. Wilson, L. Pooley, M. Lobban, S. L. Griffiths, A. M. Campbell, J. Beattie, C. Daly, and M. D. Houslay. 1995. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem. J. 306:801-809.
62. Shakur, Y., J. G. Pryde, and M. D. Houslay. 1993. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem. J. 292:677-686.
63. O'Connell, J. C., J. F. McCallum, I. McPhee, J. Wakefield, E. S. Houslay, W. Wishart, G. Bolger, M. Frame, and M. D. Houslay. 1996. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A). Biochem. J. 318:255-262.
64. Mayer, B. J., and M. J. Eck. 1995. SH3 domains: minding your p's and q's. Curr. Biol. 5:364-367.
65. McPhee, I., L. Pooley, M. Lobban, G. Bolger, and M. D. Houslay. 1995. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem. J. 310:965-974.
66. Sette, C., S. Iona, and M. Conti. 1994. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269:9245-9252.
67. Sette, C., E. Vicini, and M. Conti. 1994. The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem. 269:18271-18274.
68. Torphy, T. J., J. M. Stadel, M. Burman, L. B. Cieslinski, M. M. McLaughlin, J. R. White, and G. P. Livi. 1992. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem. 267:1798-1804.
69. Krebs, E. G., and J. A. Beavo. 1979. Phosphorylation-dephosphorylation of enzymes. Annu. Rev. Biochem. 48:923-959.
70. Kuehl, F. A., M. E. Zanetti, D. D. Soderman, D. K. Miller, and E. A. Ham. 1987. Cyclic AMP-dependent regulation of lipid mediators in white cells: a unifying concept for explaining the efficacy of theophylline in asthma. Am. J. Respir. Dis. 136:210-213.
71. Bourne, H. R., L. M. Lichtenstein, K. L. Melmon, C. S. Henny, Y. Weinstein, and G. M. Shearer. 1974. Modulation of inflammation and immunity by cyclic AMP: receptors for vasoactive hormones and mediators of inflammation regulate many leukocyte functions. Science 184: 19-28.
72. Kammer, G. M. 1988. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9: 222-229.
73. Moore, A. R., and D. A. Willoughby. 1995. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 101:387-389.
74. 2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150:5321-5329.
75. 2+ for production of IFN-gamma by a cytolytic T cell clone is posttranscriptional. J. Immunol. 146:2382-2387.
76. Vazquez, A., M. T. Auffredou, P. Galanaud, and G. Leca. 1991. Modulation of IL-2- and IL-4-dependent human B cell proliferation by cyclic AMP. J. Immunol. 146:4222-4227.
77. 1. Cell Immunol. 137:36-45.
78. Phipps, R. P., S. H. Stein, and R. L. Roper. 1991. A new view of prostaglandin D regulation of the immune response. Immunol. Today 12: 349-352.
79. Karin, M., and T. Smeal. 1992. Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem. Sci. 17:418-422.
80. Torphy, T. J. 1994. Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends. Pharmacol. Sci. 15:370-374.
81. Torphy, T. J., M. Burman, L. B. Huang, S. Horohonich, and L. B. Cieslinski. 1987. Regulation of cAMP content and cAMP-dependent protein kinase activity in airway smooth muscle. Prog. Clin. Biol. Res. 245:263-275.
82. Schramm, C. M., and M. M. Grunstein. 1992. Assessment of signal transduction mechanisms regulating airway smooth muscle contractility. Am. J. Physiol. 262:L119-L139.
83. Giembycz, M. A., and D. Raeburn. 1991. Putative substrates for cyclic nucleotide-dependent protein kinases and the control of airway smooth muscle tone. J. Anton. Pharmacol. 11:365-398.
84. Kotlikoff, M. I., and K. E. Kamm. 1996. Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscle. Annu. Rev. Physiol. 58:115-141.
85. Kume, H., I. P. Hall, R. J. Washabau, K. Takagi, and M. I. Kotlikoff. 1994. Beta-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. J. Clin. Invest. 93:371-379.
86. Kume, H., M. P. Graziano, and M. I. Kotlikoff. 1992. Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 89:11051-11055.
87. Dunnill, M. S., G. R. Massarella, and J. A. Anderson. 1969. A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema. Thorax 24:176-179.
88. Kuwano, K., C. H. Bosken, P. D. Pare, T. R. Bai, B. R. Wiggs, and J. C. Hogg. 1993. Small airways dimensions in asthma and chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 148:1220-1225.
89. Pastan, I., G. S. Johnson, and W. B. Anderson. 1975. Role of cyclic nucleotides in growth control. Annu. Rev. Biochem. 44:491-522.
90. Friedman, D. L., R. A. Johnson, and C. E. Zeilig. 1976. The role of cyclic nucleotides in the cell cycle. Adv. Cyclic Nucleotide Res. 7:69-114.
91. Dumont, J. E., J. C. Jauniaux, and P. P. Roger. 1989. The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem. Sci. 14: 67-71.
92. Panettieri, R. A., M. D. Cohen, and G. Dilgen. 1993. Airway smooth muscle cell proliferation is inhibited by microinjection of the catalytic subunit of cAMP dependent protein kinase (abstract). Am. Rev. Respir. Dis. 147:A252.
93. Panettieri, R. A., N. A. Rubinstein, B. Feuerstein, and M. I. Kotlikoff. 1991. β-Adrenergic inhibition of airway smooth muscle cell proliferation (abstract). Am. Rev. Respir. Dis. 143:A608.
94. Tomlinson, P. R., J. W. Wilson, and A. G. Stewart. 1995. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem. Pharmacol. 49:1809-1819.
95. Tomlinson, P. R., J. W. Wilson, and A. G. Stewart. 1994. Inhibition by salbutamol of the proliferation of human airway smooth muscle cells grown in culture. Br. J. Pharmacol. 111:641-647.
96. Hay, D. W. P., S. G. Farmer, and R. G. Goldie. 1994. Airway epithelial modulation of inflammatory mediators. In R. G. Goldie, editor. Immunopharmacology of Epithelial Barriers. Academic Press, San Diego, CA. 119-146.
97. Adler, K. B., B. M. Fischer, D. T. Wright, L. A. Cohn, and S. Becker. 1994. Interactions between respiratory epithelial cells and cytokines: relationships to lung inflammation. Ann. N.Y. Acad. Sci. 725:128-145.
98. - secretion by Clara cells. Am. J. Respir. Cell Mol. Biol. 13:344-351.
99. Welsh, M. J. 1987. Effect of phorbol ester and calcium ionophore on chloride secretion in canine tracheal epithelium. Am. J. Physiol. 253: C828-C834.
100. Tamaoki, J., M. Kondo, and T. Takizawa. 1989. Effect of cAMP on ciliary function in rabbit tracheal epithelial cells. J. Appl. Physiol. 66: 1035-1039.
101. Tamaoki, J., K. Kobayashi, N. Sakai, T. Kanemura, S. Horii, K. Isono, S. Takeuchi, A. Chiyotani, I. Yamawaki, and T. Takizawa. 1991. Atrial natriuretic factor inhibits ciliary motility in cultured rabbit tracheal epithelium. Am. J. Physiol. 260:C201-C205.
102. Stelzner, T. J., J. V. Weil, and R. F. O'Brien. 1989. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J. Cell Physiol. 139:157-166.
103. Seifert, A. F., W. J. Thompson, A. Taylor, W. H. Wilborn, J. Barnardt, and J. Haynes. 1992. Reversal of increased microvascular permeability associated with ischemia-reperfusion: role of cAMP. J. Appl. Physiol. 72:389-395.
104. Suttorp, N., S. Hippenstiel, M. Fuhrmann, M. Krull, and T. Podzuweit. 1996. Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability. Am. J. Physiol. 270:C778-C785.
105. Pober, J. S., M. R. Slowik, L. G. De Luca, and A. J. Ritchie. 1993. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J. Immunol. 150:5114-5123.
106. Belvisi, M. G., H. J. Patel, T. Takahashi, P. J. Barnes, and M. A. Giembycz. 1996. Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline. Br. J. Pharmacol. 117:1413-1420.
107. Zhang, X. Y., M. A. Olszewski, and N. E. Robinson. 1995. Beta 2-adrenoceptor activation augments acetylcholine release from tracheal parasympathetic nerves. Am. J. Physiol. 268:L950-L956.
108. Peachell, P. T., B. J. Undem, R. P. Schleimer, D. W. MacGlashan, Jr., L. M. Lichtenstein, L. B. Cieslinski, and T. J. Torphy. 1992. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol. 148:2503-2510.
109. Kleine-Tebbe, J., L. Wicht, H. Gagne, A. Friese, W. Schunack, C. Schudt, and G. Kunkel. 1992. Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors. Agents Actions 36:200-206.
110. Frossard, N., Y. Landry, G. Pauli, and M. Ruckstuhl. 1981. Effects of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on immunological release of histamine and on lung contraction. Br. J. Pharmacol. 73:933-938.
111. Weston, M. C., N. Anderson, and P. T. Peachell. 1997. Effects of phosphodiesterase inhibitors on human lung mast-cell and basophil function. Br. J. Pharmacol. 121:287-295.
112. Tenor, H., and C. Schudt. 1996. Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. In C. Schudt, G. Dent, and K. F. Rabe, editors. Phosphodiesterase Inhibitors. Academic Press, New York. 21-40.
113. Anderson, N., and P. T. Peachell. 1994. Effect of isoenzyme-selective inhibitors of phosphodiesterase (PDE) on human lung mast cells (HLMC) (abstract). FASEB J. 8:A239.
114. Louis, R., T. Bury, J. L. Corhay, and M. Radermecker. 1992. LY 186655, a phosphodiesterase inhibitor, inhibits histamine release from human basophils, lung and skin fragments. Int. J. Immunopharmacol 14:191-194.
115. Suzuki, F., T. Kuroda, T. Kawakita, H. Manabe, S. Kitamura, K. Ohmori, M. Ichimura, H. Kase, and S. Ichikawa. 1992. New bronchodilators: 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones. J. Med. Chem. 35:4866-4874.
116. Shearer, W. T., C. L. Patke, E. B. Gilliam, H. M. Rosenblatt, K. S. Barron, and F. M. Orson. 1988. Modulation of a human lymphoblastoid B cell line by cyclic AMP: Ig secretion and phosphatidylcholine metabolism. J. Immunol. 141:1678-1686.
117. Strannegard, O., and I. L. Strannegard. 1984. Effect of cyclic AMP-elevating agents on human spontaneous IgE synthesis in vitro. Int. Arch. Allergy Appl. Immunol. 74:9-14.
118. Cooper, K. D., K. Kang, and S. C. Chan. 1985. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis in vitro. J. Invest. Dermatol. 84:477-482.
119. Chan, S. C., S. H. Li, and J. M. Hanifin. 1993. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J. Invest. Dermatol. 100:681-684.
120. Hatzelmann, A.,H. Tenor, and C. Schudt. 1995. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br. J. Pharmacol. 114:821-831.
121. Dent, G., M. A. Giembycz, P. M. Evans, K. F. Rabe, and P. J. Barnes. 1994. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther. 271:1167-1174.
122. Souness, J. E., C. M. Carter, B. K. Diocee, G. A. Hassall, L. J. Wood, and N. C. Turner. 1991. Characterization of guinea-pig eosinophil phosphodiesterase activity: assessment of its involvement in regulating superoxide generation. Biochem. Pharmacol. 42:937-945.
123. Dent, G., M. A. Giembycz, K. F. Rabe, and P. J. Barnes. 1991. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonized zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br. J. Pharmacol. 103:1339-1346.
124. Barnette, M. S., C. D. Manning, L. B. Cieslinski, M. Burman, S. B. Christensen, and T. J. Torphy. 1995. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea-pig eosinophils is correlated with inhibition of PDE IV catalytic activity. J. Pharmacol. Exp. Ther. 273:674-679.
125. Torphy, T. J., M. S. Barnette, D. W. Hay, and D. C. Underwood. 1994. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environ. Health Perspect. 102(Suppl. 10):79-84.
126. Souness, J. E., C. Maslen, S. Webber, M. Foster, D. Raeburn, M. N. Palfreyman, M. J. Ashton, and J. A. Karlsson. 1995. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br. J. Pharmacol. 115:39-46.
127. Teixeira, M. M., A. G. Rossi, M. A. Giembycz, and P. G. Hellewell. 1996. Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation. Br. J. Pharmacol. 118:2099-2106.
128. Banner, K. H., E. Moriggi, B. Daros, G. Schioppacassi, C. Semeraro, and C. P. Page. 1996. The effect of selective phosphodiesterase-3 and phosphodiesterase-4 isoenzyme inhibitors and established antiasthma drugs on inflammatory cell activation. Br. J. Pharmacol. 119: 1255-1261.
129. Cohan, V. L., H. J. Showell, D. A. Fisher, C. J. Pazoles, J. W. Watson, C. R. Turner, and J. B. Cheng. 1996. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J. Pharmacol. Exp. Ther. 278:1356-1361.
130. Kaneko, T., R. Alvarez, I. F. Ueki, and J. A. Nadel. 1995. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell. Signal. 7:527-534.
131. 4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br. J. Pharmacol. 118:1727-1735.
132. Berends, C., B. Dijkhuizen, J. G. R. Demonchy, A. E. J. Dubois, J. Gerritsen, and H. F. Kauffrnan. 1997. Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type-IV selective PDE inhibitor, rolipram. Eur. Respir. J. 10:1000-1007.
133. Tenor, H., A. Hatzelmann, R. Kupferschmidt, L. Stanciu, R. Djukanovic, C. Schudt, A. Wendel, M. K. Church, and J. K. Shute. 1995. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy 25:625-633.
134. Greten, T. F., B. Sinha, C. Haslberger, A. Eigler, and S. Endres. 1996. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-α synthesis. Eur. J. Pharmacol. 299:229-233.
135. Seldon, P. M., P. J. Barnes, K. Meja, and M. A. Giembycz. 1995. Suppression of lipopolysaccharide-induced tumor-necrosis-factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase-4-interaction with stimulants of adenylyl-cyclase. Mol. Pharmacol. 48:747-757.
136. Semmler, J., H. Wachtel, and S. Endres. 1993. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol. 15:409-410.
137. Schade, F. U., and C. Schudt. 1993. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol. 230:9-14.
138. Molnar-Kimber, K. L., L. Yonno, R. Heaslip, and B. Weichman. 1993. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 39: C77-C79.
139. Prabhakar, U., D. Lipshutz, J. O. Bartus, M. J. Slivjak, E. F. Smith, J. C. Lee, and K. M. Esser. 1994. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16:805-816.
140. Sinha, B., J. Semmler, T. Eisenhut, A. Eigler, and S. Endres. 1995. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25:147-153.
141. 3H]-rolipram binding. Biochem. Pharmacol. 51:949-956.
142. Souness, J. E., M. Griffin, C. Maslen, K. Ebsworth, L. C. Scott, K. Pollock, M. N. Palfreyman, and J. A. Karlsson. 1996. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol. 118:649-658.
143. Verghese, M. W., R. T. McConnell, A. B. Strickland, R. C. Gooding, S. A. Stimpson, D. P. Yarnall, J. D. Taylor, and P. J. Furdon. 1995. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 272:1313-1320.
144. Hichami, A., E. Boichot, N. Germain, A. Legrand, I. Moodley, and V. Lagente. 1995. Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Eur. J. Pharmacol. 291:91-97.
145. Griswold, D. E., E. F. Webb, J. Breton, J. R. White, M. J. DiMartino, E. Smith, III, M. J. Slivjak, and T. J. Torphy. 1993. Effect of the selective phosphodiesterase type IV inhibitor, rolipram on the fluid and cellular phases of the inflammatory response. Inflammation 17: 333-344.
146. Greten, T. F., A. Eigler, B. Sinha, J. Moeller, and S. Endres. 1995. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. Int. J. Immunopharmacol. 17:605-610.
147. Elliott, K. R., and E. J. Leonard. 1989. Interactions of formylmethionyl-leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes: effects on superoxide release, inositol phosphates and cAMP. FEBS Lett. 254:94-98.
148. Schudt, C., H. Tenor, and A. Hatzelmann. 1995. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 8:1179-1183.
149. Fuller, R. W., G. O'Malley, A. J. Baker, and J. MacDermot. 1988. Human alveolar macrophage activation: inhibition by forskolin but not beta-adrenoceptor stimulation or phosphodiesterase inhibition. Pulm. Pharmacol. 1:101-106.
150. Kambayashi, T., C. O. Jacob, D. Zhou, N. Mazurek, M. Fong, and G. Strassmann. 1995. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155:4909-4916.
151. Nielson, C. P., R. E. Vestal, R. J. Sturm, and R. Heaslip. 1990. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol. 86:801-808.
152. Wright, C. D., P. J. Kuipers, D. Kobylarz Singer, L. J. Devall, B. A. Klinkefus, and R. E. Weishaar. 1990. Differential inhibition of human neutrophil functions: role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem. Pharmacol. 40:699-707.
153. Schudt, C., S. Winder, S. Forderkunz, A. Hatzelmann, and V. Ullrich. 1991. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch. Pharmacol. 344:682-690.
154. al Essa, L. Y., M. Niwa, K. Kohno, M. Nozaki, and K. Tsurumi. 1995. Heterogeneity of circulating and exudated polymorphonuclear leukocytes in superoxide-generating response to cyclic AMP and cyclic AMP-elevating agents: investigation of the underlying mechanism. Biochem. Pharmacol. 49:315-322.
155. Ottonello, L., M. P. Morone, P. Dapino, and F. Dallegri. 1995. Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin. Exp. Immunol. 101:502-506.
156. Ottonello, L., M. P. Morone, P. Dapino, and F. Dallegri. 1995. Tumour necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents. Br. J. Haematol. 91:566-570.
157. Nourshargh, S., and J. R. S. Hoult. 1986. Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors. Eur. J. Pharmacol. 122:205-212.
158. Barnette, M. S., S. B. Christensen, D. M. Essayan, M. Grous, U. Prabhakar, J. A. Rush, A. Kagey-Sobotka, and T. J. Torphy. 1997. SB 207499, a potent and selective second generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 283, (in press).
159. Derian, C. K., R. J. Santulli, P. E. Rao, H. F. Solomon, and J. A. Barrett. 1995. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J. Immunol. 154:308-317.
160. Robicsek, S. A., D. K. Blanchard, J. Y. Djeu, J. J. Krzanowski, A. Szentivanyi, and J. B. Polson. 1991. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42: 869-877.
161. Robicsek, S. A., J. J. Krzanowski, A. Szentivanyi, and J. B. Polson. 1989. High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human T-lymphocytes. Biochem. Biophys. Res. Commun. 163:554-560.
162. + T lymphocytes. Clin. Exp. Allergy 25:616-624.
163. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118:1945-1958.
164. Essayan, D. M., S.-K. Huang, B. J. Undem, A. Kagey-Sobotka, and L. M. Lichtenstein. 1994. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Immunol. 153:3408-3413.
165. Banner, K. H., N. M. Roberts, and C. P. Page. 1995. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br. J. Pharmacol. 116:3169-3174.
166. Essayan, D. M., S.-K. Huang, A. Kagey-Sobotka, and L. M. Lichtenstein. 1995. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells. Am. J. Respir. Cell Mol. Biol. 13:692-702.
167. Crocker, I. C., R. G. Townley, and M. M. Khan. 1996. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacol. 31:223-235.
168. Essayan, D. M., S. K. Huang, A. Kagey-Sobotka, and L. M. Lichtenstein. 1997. Differential efficacy of lymphocyte-selective and monocyte-selective pretreatment with a type-4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene-expression. J. Allergy Clin. Immunol. 99:28-37.
169. Giustina, T. A., S. C. Chan, M. L. Thiel, J. W. Baker, and J. M. Hanifin. 1984. Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy. J. Allergy Clin. Immunol. 74:252-257.
170. Chan, S. C., and J. M. Hanifin. 1993. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J. Lab. Clin. Med. 121:44-51.
171. 2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J. Immunol. 148:2845-2852.
172. Mary, D., C. Aussel, B. Ferrua, and M. Fehlmann. 1987. Regulation of interleukin 2 synthesis by cAMP in human T cells. J. Immunol. 139: 1179-1184.
173. Van Wauwe, J., F. Aerts, H. Walter, and M. de Boer. 1995. Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. Inflamm. Res. 44:400-405.
174. Johnson, K. W., B. H. Davis, and K. A. Smith. 1988. cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1. Proc. Natl. Acad. Sci. U.S.A. 85:6072-6076.
175. Lingk, D. S., M. A. Chan, and E. W. Gelfand. 1990. Increased cyclic adenosine monophosphate levels block progression but not initiation of human T cell proliferation. J. Immunol. 145:449-455.
176. Essayan, D. M., A. Kagey-Sobotka, L. M. Lichtenstein, and S. K. Huang. 1997. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones. Biochem. Pharmacol. 53:1055-1060.
177. Essayan, D. M., A. Kagey-Sobotka, L. M. Lichtenstein, and S. K. Huang. 1997. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 282:505-512.
178. Torphy, T. J., B. J. Undem, L. B. Cieslinski, M. A. Luttmann, M. K. Reeves, and D. W. P. Hay. 1993. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther. 265:1213-1223.
179. De Boer, J., A. J. Philpott, R. G. van Amsterdam, M. Shahid, J. Zaagsma, and C. D. Nicholson. 1992. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 106:1028-1034.
180. Rabe, K. F., H. Tenor, G. Dent, C. Schudt, S. Liebig, and H. Magnussen. 1993. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am. J. Physiol. 264:L458-L464.
181. Cortijo, J., J. Bou, J. Beleta, I. Cardelús, J. Llenas, E. Morcillo, and R. W. Gristwood. 1993. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br. J. Pharmacol. 108:562-568.
182. m cyclic AMP phosphodiesterase in intact canine trachealis by SK&F 94836: mechanical and biochemical responses. J. Pharmacol. Exp. Ther. 246:843-850.
183. Torphy, T. J., H. L. Zhou, M. Burman, and L. B. F. Huang. 1991. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis. Mol. Pharmacol. 39:376-384.
184. Zhou, H. L., and T. J. Torphy. 1991. Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators. J. Pharmacol. Exp. Ther. 258: 972-978.
185. Souness, J. E., G. A. Hassall, and D. P. Parrott. 1992. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44:857-866.
186. 2 secretion (abstract). Am. J. Respir. Crit. Care Med. 149:A986.
187. Kelley, T. J., L. al-Nakkash, and M. L. Drumm. 1995. CFTR-mediated chloride permeability is regulated by Type III phosphodiesterases in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 13:657-664.
188. Suttorp, N., P. Ehreiser, S. Hippenstiel, M. Fuhrmann, M. Krull, H. Tenor, and C. Schudt. 1996. Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Lung 174:181-194.
189. Richardson, J., and J. Beland. 1976. Nonadrenergic inhibitory nervous system in human airways. J. Appl. Physiol. 41:764-771.
190. Belvisi, M. G., C. D. Stretton, M. Yacoub, and P. J. Barnes. 1992. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in human airways. Eur. J. Pharmacol. 210:221-222.
191. G-nitro-L-arginine of nonadrenergic noncholinergic-mediated relaxations of human isolated central and peripheral airways. Am. Rev. Respir. Dis. 146:1543-1547.
192. Belvisi, M. G., J. K. Ward, J. A. Mitchell, and P. J. Barnes. 1995. Nitric oxide as a neurotransmitter in human airways. Arch. Int. Pharmacodyn. Ther. 329:97-110.
193. Lincoln, T. M., P. Komalavilas, N. J. Boerth, L. A. MacMillan Crow, and T. L. Cornwell. 1995. cGMP signaling through cAMP- and cGMP-dependent protein kinases. Adv. Pharmacol. 34:305-322.
194. Ward, J. K., P. J. Barnes, S. Tadjkarimi, M. H. Yacoub, and M. G. Belvisi. 1995. Evidence for the involvement of cGMP in neural bronchodilator responses in human trachea. J. Physiol. (Lond.) 483:525-536.
195. Ellis, J. E. 1997. Role of soluble guanylyl cyclase in the relaxations to a nitric oxide donor and to nonadrenergic nerve stimulation in guinea pig trachea and human bronchus. J. Pharmacol. Exp. Ther. 280:1215-1218.
196. Ellis, J. L., and N. D. Conanan. 1995. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea. J. Pharmacol. Exp. Ther. 272:997-1004.
197. Undem, B. J., S. N. Meeker, and J. Chen. 1994. Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 271:811-817.
198. Patel, H. J., M. A. Giembycz, P. J. Barnes, and M. G. Belvisi. 1995. Suppression of acetylcholine release from guinea-pig trachea by inhibition of phosphodiesterase (abstract). Am. J. Respir. Crit. Care Med. 151:A819.
199. Howell, R. E., B. D. Sickels, and S. L. Woeppel. 1993. Pulmonary anti-allergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs. J. Pharmacol. Exp. Ther. 264:609-615.
200. Underwood, D. C., R. R. Osborn, L. B. Novak, J. K. Matthews, S. J. Newsholme, B. J. Undem, J. M. Hand, and T. J. Torphy. 1993. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J. Pharmacol. Exp. Ther. 266:306-313.
201. Nagai, H., H. Takeda, T. Iwama, S. Yamaguchi, and H. Mori. 1995. Studies on anti-allergic action of AG 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways. Jpn. J. Pharmacol. 67:149-156.
202. Raeburn, D., S. L. Underwood, S. A. Lewis, V. R. Woodman, C. H. Battram, A. Tomkinson, S. Sharma, R. Jordan, J. E. Souness, S. E. Webber, and J.-A. Karlsson. 1994. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br. J. Pharmacol. 113:1423-1431.
203. Underwood, D. C., C. J. Kotzer, S. Bochnowicz, R. R. Osborn, M. A. Luttmann, D. W. Hay, and T. J. Torphy. 1994. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther. 270:250-259.
204. Hughes, B., D. Howat, H. Lisle, M. Holbrook, T. James, N. Gozzard, K. Blease, P. Hughes, R. Kingaby, G. Warrellow, R. Alexander, J. Head, E. Boyd, M. Eaton, M. Perry, M. Wales, B. Smith, R. Owens, C. Catterall, S. Lumb, A. Russell, R. Allen, M. Merriman, D. Bloxham, and G. Higgs. 1996. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol. 118:1183-1191.
205. Gozzard, N., A. el Hashim, C. M. Herd, S. M. Blake, M. Holbrook, B. Hughes, G. A. Higgs, and C. P. Page. 1996. Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits. Br. J. Pharmacol. 118:1201-1208.
206. Turner, C. R., C. J. Andersen, W. B. Smith, and J. W. Watson. 1994. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am. J. Respir. Crit. Care Med. 149:1153-1159.
207. Gozzard, N., C. M. Herd, S. M. Blake, M. Holbrook, B. Hughes, G. A. Higgs, and C. P. Page. 1996. Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits. Br. J. Pharmacol. 117:1405-1412.
208. Danahay, H., and K. J. Broadley. 1997. Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration. Br. J. Pharmacol. 120:289-297.
209. Banner, K. H., and C. P. Page. 1995. Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitive guinea-pigs. Br. J. Pharmacol. 114:3-98.
210. Elwood, W., J. Sun, P. J. Barnes, M. A. Giembycz, and K. F. Chung. 1995. Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats. Inflamm. Res. 44:83-86.
211. Howell, R. E., L. P. Jenkins, L. E. Fielding, and D. Grimes. 1995. Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. Pulm. Pharmacol. 8:83-89.
212. Sturm, R. J., M. C. Osborne, and R. J. Heaslip. 1990. The effect of phosphodiesterase inhibitors on pulmonary inflammatory cell influx in ovalbumin sensitized guinea pigs. J. Cell. Biochem. 14C:337.
213. Underwood, D. C., S. Bochnowicz, R. Osborn, D. Hay, P. D. Gorycki, S. B. Christensen, and T. J. Torphy. 1997. Anti-asthmatic potential of the second generation phosphodiesterase 4 inhibitor, SB 207499. Eur. Respir. J. 10:313s.
214. Lagente, V., I. Moodley, S. Perrin, G. Mottin, and J.-L. Junien. 1994. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur. J. Pharmacol. 255:153-156.
215. Lagente, V., M.-P. Pruniaux, J.-L. Junien, and I. Moodley. 1995. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am. J. Respir. Crit. Care Med. 151:1720-1724.
216. Banner, K. H., F. Marchini, A. Buschi, E. Moriggi, C. Semeraro, and C. P. Page. 1995. The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. Pulm. Pharmacol. 8:37-42.
217. Santing, R. E., C. G. Olymuldfer, K. Van der Molen, H. Meurs, and J. Zaagsma. 1995. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. Eur. J. Pharmacol. 275:75-82.
218. Howell, R. E., L. P. Jenkins, and D. E. Howell. 1995. Inhibition of lipopolysaccharide-induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs. J. Pharmacol. Exp. Ther. 275:703-709.
219. Turner, C. R., K. M. Esser, and E. B. Wheeldon. 1993. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Circ. Shock 39:237-245.
220. Holbrook, M., N. Gozzard, T. James, G. Higgs, and B. Hughes. 1996. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. Br. J. Pharmacol. 118:1192-1200.
221. Raeburn, D., and J. A. Karlsson. 1993. Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea-pig airways in vivo. J. Pharmacol. Exp. Ther. 267: 1147-1152.
222. Ortiz, J. L., J. Cortijo, J. M. Valles, J. Bou, and E. J. Morcillo. 1993. Rolipram inhibits airway microvascular leakage induced by platelet-activating factor, histamine and bradykinin in guinea-pigs. J. Pharmacol. 45:1090-1092.
223. Underwood, D. C., J. K. Matthews, R. R. Osborn, S. Bochnowicz, and T. J. Torphy. 1997. The influence of endogenous catecholamines on the inhibitory effects of rolipram against early-phase and late-phase response to antigen in the guinea-pig. J. Pharmacol. Exp. Ther. 280: 210-219.
224. Cheng, J. B., J. W. Watson, C. J. Pazoles, J. D. Eskra, R. J. Griffiths, V. L. Cohan, C. R. Turner, H. J. Showell, and E. R. Pettipher. 1997. The phosphodiesterase type-4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFα) production in mice: effect of adrenalectomy. J. Pharmacol. Exp. Ther. 280:621-626.
225. Heaslip, R. J., S. K. Buckley, B. D. Sickels, and D. Grimes. 1991. Bronchial vs. cardiovascular activities of selective phosphodiesterase inhibitors in the anesthetized beta-blocked dog. J. Pharmacol. Exp. Ther. 257:741-747.
226. Murray, K. J., R. J. Eden, P. J. England, J. Dolan, D. C. Grimsditch, C. A. Stutchbury, B. Patel, M. L. Reeves, A. Worby, T. J. Torphy, L. M. Wood, B. H. Warrington, and W. J. Coates. 1991. Potential use of selective phosphodiesterase inhibitors in the treatment of asthma. Agents Actions Suppl. 34:27-46.
227. Murray, K. J., R. J. Eden, J. S. Dolan, D. C. Grimsditch, C. A. Stutchbury, B. Patel, A. Knowles, A. Worby, J. A. Lynham, and W. J. Coates. 1992. The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function. Br. J. Pharmacol. 107:463-470.
228. m cyclic AMP phosphodiesterase in tracheal relaxation and bronchodilation in the guinea pig. J. Pharmacol. Exp. Ther. 251:199-206.
229. Heaslip, R. J., L. J. Lombardo, J. M. Golankiewkz, B. A. Ilsemann, D. Y. Evans, B. D. Sickels, J. K. Mudrick, J. Bagli, and B. M. Weichman. 1994. Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J. Pharmacol. Exp. Ther. 268:888-896.
230. Turner, N. C., J. S. Dolan, D. Grimsditch, J. Lamb, A. Worby, K. J. Murray, W. J. Coates, and B. H. Warrington. 1994. Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea-pig. Br. J. Pharmacol. 111:1198-1204.
231. Hanifin, J. M., and S. C. Chan. 1995. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J. Invest. Dermatol. 105:84S-88S.
232. Torphy, T. J., H. L. Zhou, and L. B. Cieslinski. 1992. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exp. Ther. 263:1195-1205.
233. Swinnen, J. V., D. R. Joseph, and M. Conti. 1989. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc. Natl. Acad. Sci. U.S.A. 86:8197-3201.
234. Swinnen, J. V., K. E. Tsikalas, and M. Conti. 1991. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J. Biol. Chem. 266:18370-18377.
235. Vicini, E., and M. Conti. 1997. Characterization of an intronic promoter of a cyclic adenosine-3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol. Endocrinol. 11:839-850.
236. Kochetkova, M., F. M. Burns, and J. E. Souness. 1995. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram. Biochem. Pharmacol. 50:2033-2038.
237. Erdogan, S., and M. D. Houslay. 1997. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem. J. 321:165-175.
238. Giembycz, M. A. 1996. Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Trends. Pharmacol. Sci. 17:331-336.
239. Pearce, N., J. Grainger, M. Atkinson, M. Burgess, C. Culling, H. Windom, and R. Beasley. 1990. Case-control study of prescribed fenoterol and death from asthma in New Zealand. Thorax 45:170-175.
240. Sears, M. R., D. R. Taylor, C. G. Print, C. D. Lake, Q. Li, E. M. Flannery, D. M. Yates, M. K. Lucas, and G. P. Herbison. 1990. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336: 1391-1396.
241. Spitzer, W. O., S. Suissa, P. Ernst, R. I. Horwitz, B. Habbick, D. Cockcroft, J. F. Boivin, M. McNutt, S. Buist, and A. S. Rebuck. 1992. The use of β-agonists and the risk of death and near death from asthma. N. Engl. J. Med. 326:501-506.
242. 2-adrenoceptor agonists in asthma. Trends. Pharmacol. Sci. 13:20-23.
243. Nelson, H. S., S. J. Szefler, and R. J. Martin. 1991. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental? Am. J. Respir. Dis. 144:249-250.
244. 2-agonists. Lancet 337: 717-720.
245. Torphy, T. J., W. E. DeWolf, Jr., D. W. Green, and G. P. Livi. 1993. Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions Suppl. 43:51-71.
246. Cockcroft, D. W., C. P. McParland, S. A. Britto, V. A. Swystun, and B. C. Rutherford. 1993. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 342:833-837.
247. Grewe, S. R., S. C. Chan, and J. M. Hanifin. 1982. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J. Allergy Clin. Immunol. 70:452-457.
248. Hanifin, J. M. 1989. Pharmacological abnormalities in atopic dermatitis. Allergy 44:S41-S46.
249. Holden, C. A., S. C. Chan, and J. M. Hanifin. 1986. Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J. Invest. Dermatol. 87:372-376.
250. Parker, C. W., and J. W. Smith. 1973. Alterations in cyclic adenosine monophosphate metabolism in human bronchial asthma: I. Leukocyte responsiveness to β-adrenergic agents. J. Clin. Invest. 52:48-59.
251. Busse, W. W. 1977. Decreased granulocyte response to isoproterenol in asthma during upper respiratory tract infections. Am. J. Respir. Dis. 115:783-789.
252. Butler, J. M., S. C. Chan, S. Stevens, and J. M. Hanifin. 1983. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J. Allergy Clin. Immunol. 71: 490-497.
253. Chan, S. C., S. R. Grewe, S. R. Stevens, and J. M. Hanifin. 1982. Functional desensitization due to stimulation of cyclic AMP-phosphodiesterase in human mononuclear leukocytes. J. Cyclic Nucleotide Res. 8:211-224.
254. Holden, C. A., S. C. Chan, S. Norris, and J. M. Hanifin. 1987. Histamine induced elevation of cyclic AMP phosphodiesterase activity in human monocytes. Agents Actions 22:36-42.
255. Sawai, T., K. Ikai, and M. Uehara. 1995. Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis. Br. J. Dermatol. 132:22-24.
256. Torphy, T. J., G. P. Livi, J. M. Balcarek, J. R. White, F. H. Chilton, and B. J. Undem. 1992. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. Adv. Second Messenger Phosphoprotein Res. 25:289-305.
257. Rudd, R. M., A. R. Gellert, P. R. Studdy, and D. M. Geddes. 1983. Inhibition of exercise-induced asthma by an orally absorbed mast cell stabiliser (M&B 22,948). Br. J. Dis. Chest 77:78-86.
258. Reiser, J., Y. Yeang, and J. O. Warner. 1986. The effect of zaprinast (M&B 22,948, an orally absorbed mast cell stabilizer) on exercise-induced asthma in children. Br. J. Dis. Chest 80:157-163.
259. Leeman, M., P. Lejeune, C. Melot, and R. Maeije. 1987. Reduction in pulmonary hypertension and airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest 91:662-666.
260. Fujimura, M., Y. Kamio, M. Saito, T. Hashimoto, and T. Matsuda. 1995. Bronchodilator and bronchoprotective effects of cilostazol in human in vivo. Am. J. Respir. Crit. Care Med. 151:222-225.
261. Skoyles, J. R., and K. M. Sherry. 1992. Pharmacology, mechanisms of action and uses of selective phosphodiesterase inhibitors. Br. J. Anaesth. 68:293-302.
262. Israel, E. P., M. Mathur, D. Tashkin, and J. M. Drazen. 1988. LY186655 prevents bronchospasm in asthma of moderate severity. Chest 94:71S.
263. Hughes, B., R. Owens, M. Perry, G. Warrellow, and R. Allen. 1997. PDE-4 inhibitors: the use of molecular-cloning in the design and development of novel drugs. Drug Discov. Today 2:89-101.
264. Harbinson, P. L., D. Macleod, R. Hawksworth, S. Otoole, P. J. Sullivan, P. Heath, S. Kilfeather, C. P. Page, J. Costello, S. T. Holgate, and T. H. Lee. 1997. The effect of a novel orally-active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur. Respir. J. 10:1008-1014.
265. Foster, R. W., K. Rakshi, J. R. Carpenter, and R. C. Small. 1992. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AG 21-132 in healthy volunteers during a methacholine challenge test. Br. J. Clin. Pharmacol. 34:527-534.
266. Brunee, T., R. Engelstatter, V. W. Steinijans, and W. Kunkel. 1992. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur. Respir. J. 5:982-985.
267. Ukena, D., K. Rentz, C. Reiber, and G. W. Sybrecht. 1995. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respir. Med. 89:441-444.
268. Hood, W. B. 1989. Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine. Am. J. Cardiol. 63:46A-53A.
269. Colucci, W. S., R. F. Wright, and E. Braunwald. 1986. New positive inotropic agents in the treatment of congestive heart failure: 2. Mechanisms of action and recent clinical developments. N. Engl. J. Med. 314:349-358.
270. Naccarelli, G. V., and R. A. Goldstein. 1989. Electrophysiology of phosphodiesterase inhibitors. Am. J. Cardiol. 63:35A-40A.
271. Muller, B., C. Lugnier, and J.-C. Stoclet. 1990. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. J Cardiovasc. Pharmacol. 16:796-803.
272. Horowski, R., and M. Sastre-Y-Hernandez. 1985. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr. Ther. Res. 38:23-29.
273. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 39:120-125.
274. Barnette, M. S., M. Grous, L. B. Cieslinski, M. Burman, S. B. Christensen, and T. J. Torphy. 1995. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther. 273:1396-1402.
275. Souness, J. E., and S. Rao. 1997. Proposal for pharmacologically distinct conformers of PDE4 cyclic-AMP phosphodiesterases. Cell. Signal. 9:227-236.
276. Barnette, M. S., S. B. Christensen, D. C. Underwood, and T. J. Torphy. 1997. Phosphodiesterase 4: biological underpinnings for the design of improved inhibitors. Pharmacol. Rev. Commun. 8:65-73.
277. Carpenter, D. O., D. B. Briggs, A. P. Knox, and N. Strominger. 1988. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J. Neurophys. 59:358-369.
278. Heaslip, R. J., and D. Y. Evans. 1995. Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur. J. Pharmacol. 286:281-290.
279. Rocque, W. J., W. D. Holmes, I. R. Patel, R. W. Dougherty, O. Ittoop, L. Overton, C. R. Hoffman, G. B. Wisely, D. H. Willard, and M. A. Luther. 1997. Detailed characterization of a purified type-4 phosphodiesterase, HSPDE4B2B: differentiation of high-affinity and low-affinity (R)-rolipram binding. Protein Express. Purification 9:191-202.
280. Saccomano, N. A., F. J. Vinick, K. Koe, J. A. Nielsen, W. M. Whalen, M. Meltz, D. Phillips, P. F. Thadieo, S. Jung, D. S. Chapin, L. A. Lebel, L. L. Russo, D. A. Helwig, J. L. Johnson, Jr., J. L. Ives, and I. H. Williams. 1991. Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkoxy)-4-methoxy-phenyl]-2-imidazolidinones. J. Med. Chem. 34:291-298.
281. 3H]rolipram binding, and reserpine-induced hypothermia in mice. Drug Dev. Res. 135-142.
282. 3H]rolipram binding. Biochem. Pharmacol. 51:949-956.
283. Souness, J. E., C. Houghton, N. Sardar, and M. T. Withnall. 1997. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a low-affinity phosphodiesterase 4 conformer. Br. J. Pharmacol. 121:743-750.
284. 3]R-rolipram binding by selective inhibitors. Biochem. J. 318:425-436.
285. Christensen, S. B., A. M. Guider, C. J. Forster, J. G. Gleason, P. E. Bender, J. M. Karpinski, M. S. Barnette, M. Burman, D. C. Underwood, C. D. Manning, M. Grous, D. E. Griswold, D. S. Ryan, D. S. Eggleston, and T. J. Torphy. 1997. 1,4-Cyclohexane carboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J. Med. Chem. (In press)
286. Torphy, T. J., G. P. Livi, and S. B. Christensen. 1993. Novel phosphodiesterase inhibitors for the therapy of asthma. Drug News Perspect. 6:203-214.
287. Nemoz, G., R. Zhang, C. Sette, and M. Conti. 1996. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett. 384:97-102.
288. Thompson, W. J., C. P. Ross, W. J. Pledger, S. J. Strada, R. L. Banner, and E. M. Hersh. 1976. Cyclic adenosine 3′:5′-monophosphate phosphodiesterase: distinct forms in human lymphocytes and monocytes. J. Biol. Chem. 251:4922-4929.
289. Fonteh, A. N., J. D. Winkler, T. J. Torphy, J. Heravi, B. J. Undem, and F. H. Chilton. 1993. Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil. J Immunol. 151:339-350.
290. Loughney, K., and K. Ferguson. 1996. Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods. In C. Schudt, G. Dent, and K. F. Rabe, editors. Phosphodiesterase Inhibitors. Academic Press, San Diego, CA. 1-19.